- Press Releases
- Notices
Press Releases To List
-
- Mar.12.2025Licensing
- Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
-
- Mar.10.2025R & D
- Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
-
- Feb.28.2025Corporate
- Ono Pharmaceutical Announces Reorganization of its US and Europe Operations
-
- Feb.25.2025R & D
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
-
- Feb.17.2025R & D
- U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Notices To List
-
- Oct.01.2024Corporate
- ONO begins Airing New Commercial “Rising to the challenges of Immuno-Oncology” in Japan
-
- Sep.30.2024Corporate
- Corporate Report 2024 has been released.
-
- Jun.21.2024Corporate
- Voting Results (Extraordinary Report) of the 76th Ordinary General Shareholders’ Meeting
-
- Jun.20.2024Corporate
- Notice to Resolutions Passed at The 76th Ordinary General shareholders’ Meeting
-
- May.23.2024Corporate
- Notice to Convene the 76th Ordinary General Shareholders' Meeting
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
